Kintara Therapeutics, Inc.

  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Academic Collaborations
    • Advisors
  • Pipeline
    • Overview
    • VAL-083
    • REM-001
  • Clinical Trials
  • News & Media
    • Press Releases
    • Publications and Abstracts
    • Presentations
    • Events
    • Recent News
  • Investors
    • Overview
    • Analyst Coverage
    • News / Events
    • Company Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • Contact
  • Careers

Press Releases

Investors

Investors

  • Overview
  • Analyst Coverage
  • News / Events
    • Overview
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Overview
    • Profile
    • Presentations
    • Management Team
    • Contacts
    • FAQ
  • Stock Data
    • Overview
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
    • Independent Directors
  • Investor Tools
    • Email Alerts
    • Contacts
    • RSS News Feed
  • News / Events

  • Overview
  • Press Releases
  • IR Calendar
  • Email Alerts

Henry Ford Cancer Institute is First in the World to Activate Two New Treatments in GBM AGILE Trial for Glioblastoma Brain Cancer

Feb 3, 2021

Kintara Announces Initiation of Patient Recruitment for VAL-083's Study Arm in the GBM AGILE Trial

Jan 13, 2021

Global Coalition for Adaptive Research, Kazia, and Kintara Announce Commencement of Kazia’s Paxalisib and Kintara’s VAL-083 in GBM AGILE Trial

Jan 6, 2021

Kintara Therapeutics to Present at the H.C. Wainwright Bioconnect 2021 Virtual Conference

Jan 5, 2021

Kintara Therapeutics to Present at the 2nd Annual Glioblastoma Drug Development Summit

Dec 3, 2020

Kintara Therapeutics Reports 10 Months Progression-Free Survival in Newly-Diagnosed MGMT-unmethylated GBM from Ongoing MD Anderson Cancer Center Phase 2 Study

Nov 19, 2020

Kintara Therapeutics Announces First Fiscal Quarter 2021 Financial Results and Recent Corporate Updates

Nov 13, 2020

Kintara and the Global Coalition for Adaptive Research Execute Agreement for VAL-083's Participation in the GBM AGILE Registrational Study

Oct 21, 2020

Kintara Therapeutics Announces Fiscal Year 2020 Financial Results and Recent Corporate Updates

Sep 21, 2020

Kintara Therapeutics Completes Final Closing of Previously Announced Private Placement For an Aggregate of $25 Million

Sep 1, 2020
RSS
    • 1...
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7
    • 8
    • 9
    • 10
    • 11
    • ...33
    © 2023 Kintara Therapeutics, Inc. All Rights Reserved.
    Privacy Policy Disclaimer Sitemap Legal Information Manage Cookie Preferences